Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices. PURPOSE: To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes. DATA SOURCES: English-language studies from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, indexed from inception through March 2015 (MEDLINE search updated through December 2015). STUDY SELECTION: Paired reviewers independently identified 179 trials and 25 observational studies of head-to-head monotherapy or metformin-based combinations. DATA EXTRACTION: Two reviewers independently assessed study quality and serially extracted data and graded the strength of evidence. DATA SYNTHESIS: Cardiovascular mortality was lower for metformin versus sulfonylureas; the evidence on all-cause mortality, cardiovascular morbidity, and microvascular complications was insufficient or of low strength. Reductions in hemoglobin A1c values were similar across monotherapies and metformin-based combinations, except that DPP-4 inhibitors had smaller effects. Body weight was reduced or maintained with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors and increased with sulfonylureas, thiazolidinediones, and insulin (between-group differences up to 5 kg). Hypoglycemia was more frequent with sulfonylureas. Gastrointestinal adverse events were highest with metformin and GLP-1 receptor agonists. Genital mycotic infections were increased with SGLT-2 inhibitors. LIMITATION: Most studies were short, with limited ability to assess rare safety and long-term clinical outcomes. CONCLUSION: The evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). On the basis of less evidence, results for add-on therapies to metformin were similar to those for monotherapies. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compounds that modulate NF-κB signalling, including metformin137,235–237, apigenin238, kaempferol238 and BAY 11–7082 (REF.118), have also been shown to decrease SASP production.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [236]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We evaluated the heterogeneity among the trials by using the I(2) statistic (11).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We generated summary treatment effects with the random-effects model estimated by using the DerSimonian and Laird method in settings of low heterogeneity (I(2) < 50%) (12) and the profile likelihood estimate in settings of high heterogeneity (I(2) ≥ 50%) (13).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Two independent reviewers assessed risk of bias in individual RCTs by using the criteria of Jadad and colleagues (9), as in our prior review (6).”
MethodDowns, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252 · cited 1×
“We used the Downs and Black tool for assessment of the risk of bias for the nonrandomized trials and observational studies (10).”
MethodEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“diet) on the relative benefits of metformin and sulfonylureas for the spectrum of long-term outcomes important in diabetes (32).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Research works printed but not linked: 1
- Wang CP, 2014, J Endocrinol Diabetes Obes, 2
Cited by
Items 201–300 of 733
Arshad, M. N., Arshad, S., Majeed, M. K., Frueh, J., Chang, C., Bilal, I., Niaz, S. I., Khan, M. S., Tariq, M. A., & Mehboob, M. Y. (2023) · ACS Omega · doi:10.1021/acsomega.3c00058 · Cited by 27
Role of metformin in the management of type 2 diabetes: recent advances
Gonzalez-Lopez, C., & Wojeck, B. S. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16511 · Cited by 28
Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis
Soberanes, S., Misharin, A. V., Jairaman, A., Morales‐Nebreda, L., McQuattie‐Pimentel, A. C., Cho, T., Hamanaka, R. B., Meliton, A. Y., Reyfman, P. A., Walter, J. M., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.001 · Cited by 27
Xing, X., Wu, K., Dong, Y., Zhou, Y., Zhang, J., Jiang, F., Hu, W., & Li, J. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107816 · Cited by 26
Therapeutic Applications of Type 2 Diabetes Mellitus Drug Metformin in Patients with Osteoarthritis
Song, P., Hwang, J. S., Park, H. C., Kim, K. K., Son, H., Kim, Y., & Lee, K. M. (2021) · Pharmaceuticals · doi:10.3390/ph14020152 · Cited by 27
“Since diabetic patients are at higher risk of bone degradation, anti-diabetic mediations may have beneficial effects against bone disorders [7,118,119].”
BackgroundIdentification of an allosteric hotspot for additive activation of PPARγ in antidiabetic effects
Li, F., Lu, S., Zheng, Z., Chen, Y., Zhao, Y., Song, K., Xue, H., Jin, L., Li, Y., Huang, C., et al. (2021) · 中国科学通报:英文版 · doi:10.1016/j.scib.2021.01.023 · Cited by 26
Phadwal, K., Koo, E., Jones, R. A., Forsythe, R. O., Tang, K., Tang, Q., CORCORAN, B. M., Caporali, A., & MacRae, V. E. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30887 · Cited by 26
“Together with atorvastatin, metformin can also improve the rate of obesity and subclinical inflammation (Maruthur et al., 2016).”
BackgroundMittman, B. G., Le, P. N. B., Payne, J. Y., Ayers, G. T., & Rothberg, M. B. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2303413 · Cited by 26
Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.354 · Cited by 33
Ye, Z., Liu, C., Zou, F. M., Cai, Y., Chen, B., Zou, Y., Mo, J., Han, T., Huang, W., Qiu, Q., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115574 · Cited by 28
Lajthia, E., Bucheit, J. D., Nadpara, P. A., Dixon, D. L., Caldas, L. M., Murchie, M., & Sisson, E. M. (2019) · Pharmacy Practice · doi:10.18549/pharmpract.2019.4.1588 · Cited by 25
Cwynar-Zając, Ł. (2021) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2021.107166 · Cited by 25
“The main target tissue of metformin is the liver, and its main effect is the reduction of glucose secretion in the liver due to the inhibition of gluconeogenesis, which leads to a reduction in blood glucose levels [1].”
BackgroundThe antioxidant and antidiabetic potentials of polyphenolic-rich extracts ofCyperus rotundus(Linn.)
Mohamed, A. I., Beseni, B. K., Msomi, N. Z., Salau, V. F., Erukainure, O. L., Aljoundi, A., & Islam, M. S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1967197 · Cited by 32
“gain, hypoglycemic shock, stomach upset, renal damage and liver failure (Kalsi et al., 2015; Maruthur et al., 2016).”
BackgroundLu, K.-T., Ho, Y., Chang, C., Lan, K., Wu, C., & Su, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10123197 · Cited by 29
Bian, X., Jiang, L., Gan, Z., Guan, X., Zhang, L., Cai, L., & Hu, X. (2019) · Molecules · doi:10.3390/molecules24203786 · Cited by 25
“These two drugs are effective in the treatment of T2DM as both single and combined therapy [12].”
BackgroundApproaches to risk assessment among older patients with diabetes
Pilla, S. J., Schoenborn, N. L., Maruthur, N. M., & Huang, E. S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1172-z · Cited by 24
Self-citationDiabetes mellitus: The pathophysiology as a canvas for management elucidation and strategies
Iheagwam, F. N., & Iheagwam, O. T. (2025) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2025.100351 · Cited by 32
Vazifekhah, S., Mohammadkhanizadeh, A., Fahanik‐Babaei, J., Hashemi, P., Alireza, M. S., & Nikbakht, F. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118066 · Cited by 24
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2020
Orozco‐Beltrán, D., Cuixart, C. B., Sánchez, J. J. A., Banegas, J. R., Cuenca, A. M. C., Gil-Guillén, V. F., Rioboó, E. M., & Pérez, J. N. (2020) · Atención Primaria · doi:10.1016/j.aprim.2020.08.002 · Cited by 30
Sun, L., Jiang, J., Zeng, Y., Zhu, J., Wang, S., Huang, D., & Cao, C. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c06030 · Cited by 24
Ko, S., Hur, K. Y., Rhee, S. Y., Kim, N. H., Moon, M. K., Park, S.-O., Lee, B., Kim, H. J., Choi, K. M., & Kim, J. H. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.298 · Cited by 24
“If metformin is not tolerable or is contraindicated, the alternative choices for monotherapy include DPP4 inhib- itors, SGLT2 inhibitors, TZDs, GLP-1RAs, SUs, glinides (meglitinide), α-glucosidase inhibitors (AGIs), and insulin according to patient circumstances (Table 2, Fig.”
InfluentialKhunti, K., Charbonnel, B. H., Cooper, A., Gomes, M. B., Ji, L., Leigh, P., Nicolucci, A., Rathmann, W., Shestakova, M. V., Siddiqui, A., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14400 · Cited by 26
Ayoub, S., Arabi, M., Al-Najjar, Y. A., Laswi, I., Outeiro, T. F., & Châari, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05051-9 · Cited by 27
“Metformin is commonly prescribed for T2DM due to its effectiveness in managing hemoglobin A1c levels, promoting weight management, and reducing cardiovascular risk, making it a preferred initial treatment choice [174].”
Asman, A. G., Hoogendoorn, C. J., McKee, M. D., & Gonzalez, J. S. (2019) · Journal of Behavioral Medicine · doi:10.1007/s10865-019-00056-x · Cited by 25
Grzmil, M., Qin, Y., Schleuniger, C., Frank, S., Imobersteg, S., Blanc, A., Spillmann, M., Berger, P., Schibli, R., & Béhé, M. P. (2020) · Theranostics · doi:10.7150/thno.45440 · Cited by 23
“Metformin is a less potent inhibitor than RAD001 and it inhibits mTORC1 indirectly via activation of AMPK, which in turn phosphorylates mTORC1 negative regulator, the tuberous sclerosis complex (TSC) 1/2 [45].”
MethodMetformin Protects against Podocyte Injury in Diabetic Kidney Disease
Lehtonen, S. H. (2020) · Pharmaceuticals · doi:10.3390/ph13120452 · Cited by 24
“Most hypoglycemic events are associated with the use of sulfonylureas and most gastrointestinal adverse events with the use of metformin and GLP-1 receptor agonists [4].”
BackgroundMethodResultInfluentialCardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective
Thompson, P. L., & Davis, T. M. E. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.10.008 · Cited by 26
Piera-Mardemootoo, C., Lambert, P., & Faillie, J. (2018) · Therapies · doi:10.1016/j.therap.2018.01.006 · Cited by 26
Gottlieb, A., Mosthael, W., Sowa, J., & Canbay, A. E. (2018) · Digestion · doi:10.1159/000493259 · Cited by 23
Oguntibeju, O. O., Aboua, Y. G., & Kachepe, P. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03817 · Cited by 24
Wang, J., Lü, Y., Min, X., Yuan, T., Wei, J., & Cai, Z. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.648212 · Cited by 23
Diabetes y enfermedad cardiovascular
Guamán, C., Acosta, W., Alvarez, C., & Hasbum, B. (2021) · Revista Uruguaya de Cardiología · doi:10.29277/cardio.36.1.4 · Cited by 35
Fralick, M., Schneeweiß, S., Redelmeier, D. A., Razak, F. A., Gomes, T., & Patorno, E. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14474 · Cited by 23
Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure
Verbrugge, F. H. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0340-1 · Cited by 25
Identification of novel α-glucosidase inhibitory peptides from the serum of Xinjiang Bactrian camels
Lin, M. F., Guo, X., Sun, R., Le, T. N., Zhao, M., & Cai, H. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109295 · Cited by 22
A novel artificial intelligence protocol to investigate potential leads for diabetes mellitus
Gong, J.-N., Zhao, L., Chen, G., Chen, X., Chen, Z., & Chen, C. Y. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10204-8 · Cited by 22
Pasqualotto, E., Watanabe, J. M. F., Gewehr, D. M., Maintinguer, R. D. S., van de Sande‐Lee, S., de Araújo, G. N., Leal, F. S., & Pinheiro, C. E. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15051 · Cited by 24
“Interestingly, the benefits of SGLT2 inhibitors expand well beyond glycaemic control, and include a reduction in blood pressure and body mass, irrespective of glycaemic status.(1,4,5) SGLT2 inhibitors also improve cardiovascular and renal outcomes in patients with diabetes.”
BackgroundHassan, I., Al‐Tamimi, J., Ebaid, H., Habila, M. A., Alhazza, I. M., & Rady, A. M. (2023) · Toxics · doi:10.3390/toxics11100867 · Cited by 22
“…approval of many other antidiabetic agents like thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists in the drug market, MTF is still the most preferred drug for DM by contemporary doctors [8].”
BackgroundYang, W., Yang, Y., Wang, Y., Gao, Z., Zhang, J., Gao, W., Chen, Y., Lü, Y., Wang, H., Zhou, L., et al. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5395 · Cited by 23
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14202 · Cited by 22
Ren, D., Qin, G., Zhao, J., Sun, Y., Zhang, B., Li, D., Wang, B., Jin, X., & Wu, H. (2020) · PubMed · Cited by 34
González‐González, J. G., Solís, R. C., González-Colmenero, A. D., Raygoza-Cortez, K., Moreno-Peña, P. J., Sánchez, A. L., McCoy, R. G., Ospina, N. S., Maraka, S., Brito, J. P., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109821 · Cited by 24
Characterizing the genetic architecture of drug response using gene-context interaction methods
Sadowski, M., Thompson, M., Mefford, J., Haldar, T., Oni‐Orisan, A., Border, R., Pazokitoroudi, A., Cai, N., Ayroles, J. F., Sankararaman, S., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100722 · Cited by 21
Perspectives on weight control in diabetes – Tirzepatide
Várkonyi, T. T., Pósa, A., Pávó, N., & Pavo, I. J. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110770 · Cited by 22
Heidarpour, M., Mojarad, M., Mazaheri‐Tehrani, S., Kachuei, A., Najimi, A., Shafie, D., & Rezvanian, H. (2024) · International Journal of Endocrinology · doi:10.1155/2024/9900213 · Cited by 23
Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments
Banerjee, S., Talukdar, I., Banerjee, A., Gupta, A. A., Balaji, A., & Aduri, R. (2019) · Journal of Biosciences · doi:10.1007/s12038-019-9962-7 · Cited by 23
Challenges and Strategies for Diabetes Management in Community-Living Older Adults
Sinclair, A. J., & Abdelhafiz, A. H. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0013 · Cited by 23
Lu, C., Chung, C., Kuo, F.-C., Chen, K.-C., Chang, C., Kuo, C., Lee, C.-H., Su, S., Liu, J., Lin, F., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092839 · Cited by 21
“First-line metformin therapy has beneficial effects on HbA1C and weight [26] and may reduce the risk of cardiovascular events and death [27].”
BackgroundOh, S. H., Lee, S. J., Noh, J., & Mo, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-86419-4 · Cited by 22
Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?
Laskar, J., Bhattacharjee, K., Sengupta, M., & Choudhury, Y. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0402-z · Cited by 23
Zarvasi, A., Jaberi, A. A., Bonabi, T. N., & Tashakori, M. (2018) · Electronic physician · doi:10.19082/7155 · Cited by 21
“Different methods are available to control type 2 diabetes symptoms, such as changing lifestyle, exercising (4), maintaining a suitable diet (5), taking oral medicines (6), and injecting insulin (7).”
MethodThe molecular mechanisms of disulfidptosis and its role in Diabetes mellitus and its complications
Zhang, Y., Ni, Q., Chen, Y., Pei, Z., & Xu, X. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118499 · Cited by 21
Buzea, A., Manu, P., Dima, L., & Correll, C. U. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2147425 · Cited by 20
“The main concern regarding this class of hypoglycemic agents is related to their risk of hypoglycemia and weight gain [95,96].”
BackgroundAdalikwu, S. A., Louis, H., Iloanya, A. C., Edet, H. O., Akem, M. U., Eno, E. A., & Manicum, A.-L. E. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00855 · Cited by 20
RetractedBouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Diabetology International · doi:10.1007/s13340-022-00605-x · Cited by 23
Monotherapy in Patients with Type 2 Diabetes Mellitus
Rhee, S. Y., Kim, H. J., Ko, S., Hur, K. Y., Kim, N. H., Moon, M. K., Park, S.-O., Lee, B., Choi, K. M., & Kim, J. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.349 · Cited by 25
Therapeutic vaccine against IL-1β improved glucose control in a mouse model of type 2 diabetes
Zhang, Y., Yu, X., Zha, J., Mao, L., Chai, J.-Q., & Liu, R. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.11.021 · Cited by 22
Liu, Y., Hu, X., Shan, X., Chen, K., & Tang, H. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0732-2 · Cited by 20
Lawrence, W. R., Hosler, A. S., Gates, M. A., Leinung, M. C., Zhang, X., Schymura, M. J., & Boscoe, F. P. (2020) · Cancer Epidemiology · doi:10.1016/j.canep.2020.101710 · Cited by 20
The Place of Sulfonylureas in Guidelines: Why Are There Differences?
Amod, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00811-3 · Cited by 23
Lee, H. W., Lee, J. S., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., & Kim, S. U. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107747 · Cited by 20
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 25
Majeed, M. A., Mundkur, L., Paulose, S., & Nagabhushanam, K. (2022) · Food & Function · doi:10.1039/d2fo01862d · Cited by 20
Metformin Suppressed CXCL8 Expression and Cell Migration in HEK293/TLR4 Cell Line
Xiao, Z., Wu, W., & Poltoratsky, V. P. (2017) · Mediators of Inflammation · doi:10.1155/2017/6589423 · Cited by 20
Liu, W., Shao, P. P., Liang, G., Bawiec, J., He, J., Aster, S. D., Wu, M. S., Chicchi, G., Wang, J. C. K., Tsao, K.-L. C., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00305 · Cited by 20
Khatami, F., Mohajeri‐Tehrani, M. R., & Tavangar, S. M. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190228102212 · Cited by 21
Challenging 2019 ESC guidelines for the management of type 2 diabetes
Scheen, A. J. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.10.006 · Cited by 20
Management of Kidney Failure in Patients with Diabetes Mellitus: What Are the Best Options?
Buades, J. M., Craver, L., y Pino, M. D. D. P., Prieto‐Velasco, M., Ruiz, J. C., Salgueira, M., de Sequera, P., & Vega, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132943 · Cited by 25
Application of Phytochemicals in Therapeutic, Food, Flavor, and Cosmetic Industries
Kawatra, A., Gupta, S., Dhankhar, R., Singh, P., & Gulati, P. (2022) · Springer eBooks · doi:10.1007/978-981-19-5779-6_4 · Cited by 35
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00723-8 · Cited by 21
Calza, G., Nyberg, E., Mäkinen, M., Soliymani, R., Cascone, A., Lindholm, D., Barborini, E., Baumann, M., Lalowski, M. M., & Eriksson, O. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00141 · Cited by 19
“This study demonstrates the power of MALDI-MSI for assessing the tissue concentration and distribution of metformin, and the technique will be useful for future studies of metformin in T2D, cancer and neurodegenerative states.”
BackgroundInfluentialJones, V., Dietze, E. C., Jovanović‐Talisman, T., McCune, J. S., & Seewaldt, V. L. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.509714 · Cited by 19
Gad, H., Hayat, T., Almuhannadi, H., Malik, B., Mussleman, P., & Malik, R. A. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108562 · Cited by 20
Li, Y., Zhao, H., Guo, Y., Duan, Y., Guo, Y., & Ding, X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.811776 · Cited by 19
Global gene expression analysis in liver of db/db mice treated with catalpol
Liu, J., Zhang, H., Yan-Bao, H. O. U., Xiao-Long, J. I. N. G., Xin-Yi, S. O. N. G., & Xiu-ping, S. (2018) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(18)30096-7 · Cited by 19
“Metformin is generally recommended as a first line treatment ([7-9]); however, it should not be used in those with severe kidney or liver problems ([10]).”
BackgroundTumor reversion: a dream or a reality
Tripathi, A., Kashyap, A., Tripathi, G., Yadav, J., Bibban, R., Aggarwal, N., Thakur, K., Chhokar, A., Jadli, M., Sah, A. K., et al. (2021) · Biomarker Research · doi:10.1186/s40364-021-00280-1 · Cited by 21
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., Antoniadis, A. P., et al. (2025) · Medicina · doi:10.3390/medicina61111903 · Cited by 23
“Meta-analyses indicate that SGLT2is lead to a dose-dependent body weight reduction of about 1.5 to 2 kg relative to placebo [53–55].”
InfluentialValenti, V. E., Chagas, A. D. S., Chedraui, P. A., de Souza, I. S., Porto, A. A., Sorpreso, I. C. E., Soares, J. M., Zangirolami-Raimundo, J., Garner, D. M., & Raimundo, R. D. (2025) · Gynecological Endocrinology · doi:10.1080/09513590.2025.2450338 · Cited by 20
Anholm, C., Kumarathurai, P., Jürs, A., Pedersen, L. R., Nielsen, O. W., Kristiansen, O. P., Fenger, M., Holst, J. J., Madsbad, S., Sajadieh, A., et al. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0438-6 · Cited by 18
Metformin protects red blood cells against rotenone induced oxidative stress and cytotoxicity
Tripathi, S. S., Singh, A. K., Akhtar, F., Chaudhary, A., & Rizvi, S. I. (2019) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2019.1620288 · Cited by 18
“Furthermore, it has been shown to have multiple biological benefits apart from lowering blood glucose and improving insulin sensitivity (Malek et al. 2013, Maruthur et al. 2016).”
BackgroundWang, W., Gao, Y., Chen, D., Wang, C., Feng, X., & Ran, X. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.007 · Cited by 19
“The adverse effects of gastrointestinal disorders in incretin-treated (especially GLP-1 receptor analogs) patients has been a consensus [2,31,32,37].”
BackgroundEvolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
Galstyan, G. R., Анатольевна, К. Е., & Александровна, Ю. Е. (2017) · Diabetes Mellitus · doi:10.14341/dm8804 · Cited by 21
Lally, J., Loughlin, A. O., Stubbs, B., Guérandel, A., O'Shea, D. B., & Gaughran, F. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1445968 · Cited by 18
Jang, J., Song, I., Sung, E., Lee, T., & Kim, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8832 · Cited by 18
Tschanz, M. P., Watts, S. A., Colburn, J. A., Conlin, P. R., & POGACH, L. M. (2017) · Europe PMC (PubMed Central) · Cited by 20
Pan, S., Li, S., Jiang, S., Shin, J., Liu, G. G., Wu, H., & Lyu, B. (2024) · The Journals of Gerontology Series A · doi:10.1093/gerona/glae108 · Cited by 18
Zhou, D., Liu, H., Zheng, L., Liu, A., Zhuan, Q., Luo, Y., Zhou, G., Meng, L., Hou, Y., Wu, G., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06631-6 · Cited by 20
ENOblock inhibits the pathology of diet-induced obesity
Cho, H., Lee, J., Um, J., Kim, S., Kim, Y., Kim, W., Kim, Y. S., Pagire, H. S., Ahn, J. H., Ahn, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36715-3 · Cited by 17
The Anti-Breast Cancer Effect and Mechanism of Glimepiride-Metformin Adduct
Long, L., Hu, X., Li, X., Zhou, D., Shi, Y., Wang, L., Zeng, H., Yu, X., & Zhou, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s240252 · Cited by 17
Douša, M., & Jireš, J. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113573 · Cited by 17
Javanshir, S. T., Yaghmaei, P., & Hajebrahimi, Z. (2018) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.29252/ijrm.16.4.275 · Cited by 18
Pinto, M., Brennan, L., Diehl, K., Lin, S., & Heacock, S. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241289959 · Cited by 18
Luo, C., Wang, X., Mao, X., Huang, H., Liu, Y., Zhao, J., Zhou, H., Liu, Z., & Li, X. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05524-w · Cited by 16
Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
Xiao, L., Nie, X., Cheng, Y., & Wang, N. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07216-9 · Cited by 16
“On top of their action in reducing glycemia, which eliminates approximately 60–100 g of glucose per day, SGLT2 inhibitors also result in a modest reduction in body weight (1–3 kg) [99, 100].”
BackgroundFawzy, M. G., Hafez, H. M., Hassan, W. E., Mostafa, A. A., & Sayed, R. A. (2022) · Microchemical Journal · doi:10.1016/j.microc.2022.107856 · Cited by 16
Metformin impairs trophoblast metabolism and differentiation in a dose-dependent manner
Nashif, S. K., Mahr, R. M., Jena, S., Jo, S., Nelson, A. B., Sadowski, D., Crawford, P. A., Puchalska, P., Alejandro, E. U., Gearhart, M. D., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1167097 · Cited by 17
“…syncytiotrophoblast, differentiation, mitochondria Introduction Metformin (1,1-dimethylbiguanide) is a first-line treatment for patients with type 2 diabetes given its ability to improve glucose levels, support weight loss, and reduce cardiovascular morbidity (Maruthur et al., 2016).”
BackgroundAdvances in the Use of Metformin for Liver Disease
Bao, J., Zhao, Y., Xu, X., & Ling, S. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673274268231215110330 · Cited by 16
Peralta, F. G., Martín, F. J. E. S., Torre, E. L. M., Mata‐Cases, M., García, J. C. F., Loiola, P. E., Lachica, L. Á., Pérez, J. A. F., Menéndez, S. A., Guisasola, F. Á., et al. (2018) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.11.010 · Cited by 20
Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study
Xu, Y., Pilla, S. J., Alexander, G. C., & Murimi, I. B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211820 · Cited by 16
Differences in National Diabetes Treatment Patterns and Trends between Older and Younger Adults
Pilla, S. J., Segal, J. B., Alexander, G. C., Boyd, C. M., & Maruthur, N. M. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15790 · Cited by 17
“Third, whereas use of DPP-4 inhibitors has increased substantially in older adults, they have lower glycemic efficacy than other classes and thus may not substitute for insulin.(14) Notably, evidence is lacking that longacting insulin is safer or more effective than newer medication classes in older adults.”
BackgroundSelf-citation
Metadata
- Authors
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S.
- Affiliations
- MetroHealth (US)
- From The Johns Hopkins University School of Medicine; The Johns Hopkins University Bloomberg School of Public Health; and Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, and Center for Health Care Research and Policy, MetroHealth/Case Western Reserve University; MetroHealth Medical Center; and Case Western Reserve University, Cleveland, Ohio.
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-06-07
- Volume
- 164
- Issue
- 11
- Pages
- 740-751
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2340898396
- Cited by
- 682
- References
- 66
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 60 · 2023: 68 · 2022: 80 · 2021: 90 · 2020: 89 · 2019: 71 · 2018: 68 · 2017: 56 · 2016: 11
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- Agency for Healthcare Research and Quality (290-2012-00007-I)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, metformin, monotherapy, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular mortality, glycemic control, HbA1c, weight loss, hypoglycemia, gastrointestinal adverse effects, genital mycotic infections, first-line therapy
- MeSH terms
- Adult, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.